Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bi-FLO: Bilastine and inflammation in Parietaria-induced allergic rhinoconjunctivitis
2016-004214-96Phase 4Terminated
- Sponsor
- Menarini Group
- Start
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of bilastine in allergic rhinoconjunctivitis (ARC), sponsored by Menarini Group. Primary endpoint: Primary response in nasal eosinophils. Started Feb 2018; status: terminated.
02
Drugs
bilastine
03
Conditions
allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on 2016-004214-96.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004214-96.